CRISPR/Cas9 system and its applications in nervous system diseases
Abstract
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system is an acquired immune system of many bacteria and archaea, comprising CRISPR loci, Cas genes, and its associated proteins. This system can recognize exogenous DNA and utilize the Cas9 protein’s nuclease activity to break DNA double-strand and to achieve base insertion or deletion by subsequent DNA repair. In recent years, multiple laboratory and clinical studies have revealed the therapeutic role of the CRISPR/Cas9 system in neurological diseases. This article reviews the CRISPR/Cas9-mediated gene editing technology and its potential for clinical application against neurological diseases.
References
Zhang HX, Zhang Y, Yin H. Genome editing with mRNA encoding ZFN, TALEN, and Cas9. Mol Ther. 2019;27(4):735–746.
Mojica FJM, Díez-Villaseñor C, García-Martínez J, et al. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology (Read). 2009;155(Pt 3):733–740.
Zhu S, Li W, Liu J, et al. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat Biotechnol. 2016;34(12):1279–1286.
Li J, Meng X, Zong Y, et al. Gene replacements and insertions in rice by intron targeting using CRISPR-Cas9. Native Plants. 2016;2:16139.
Stachler AE, Marchfelder A. Gene repression in haloarchaea using the CRISPR (clustered regularly interspaced short palindromic repeats)-Cas Ⅰ-B system. J Biol Chem. 2016;291(29):15226–15242.
Joung J, Konermann S, Gootenberg JS, et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc. 2017;12(4):828–863.
Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–821.
Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol. 2000;57(3):418–420.
Lu L, Yu X, Cai Y, et al. Application of CRISPR/Cas9 in Alzheimer’s disease. Front Neurosci. 2021;15:803894.
Safari F, Hatam G, Behbahani AB, et al. CRISPR system: a highthroughput toolbox for research and treatment of Parkinson’s disease. Cell Mol Neurobiol. 2020;40(4):477–493.
Qin Y, Li S, Li XJ, et al. CRISPR-based genome-editing tools for Huntington’s disease research and therapy. Neurosci Bull. 2022;38(11):1397–1408.
Al-Sammarraie N, Ray SK. Applications of CRISPR-Cas9 technology to genome editing in glioblastoma multiforme. Cells. 2021;10(9):2342.
Carpenter JC, Lignani G. Gene editing and modulation: the holy grail for the genetic epilepsies? Neurotherapeutics. 2021;18(3):1515–1523.
Yun Y, Ha Y. CRISPR/Cas9-mediated gene correction to understand ALS. Int J Mol Sci. 2020;21(11):3801.
Sorek R, Kunin V, Hugenholtz P. CRISPR: a widespread system that provides acquired resistance against phages in bacteria and Archaea. Nat Rev Microbiol. 2008;6(3):181–186.
Lillestøl RK, Shah SA, Brügger K, et al. CRISPR families of the crenarchaeal genus Sulfolobus: bidirectional transcription and dynamic properties. Mol Microbiol. 2009;72(1):259–272.
Hale C, Kleppe K, Terns RM, et al. Prokaryotic silencing (psi) RNAs in Pyrococcus furiosus. RNA. 2008;14(12):2572–2579.
Carte J, Wang R, Li H, et al. Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes. Genes Dev. 2008;22(24):3489–3496.
Chylinski K, Makarova KS, Charpentier E, et al. Classification and evolution of type Ⅱ CRISPR-Cas systems. Nucleic Acids Res. 2014;42(10):6091–6105.
Makarova KS, Haft DH, Barrangou R, et al. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol. 2011;9(6):467–477.
Barrangou R, Fremaux C, Deveau H, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315(5819):1709–1712.
Wiedenheft B, Zhou K, Jinek M, et al. Structural basis for DNase activity of a conserved protein implicated in CRISPR-mediated genome defense. Structure. 2009;17(6):904–912.
Beloglazova N, Brown G, Zimmerman MD, et al. A novel family of sequence-specific endoribonucleases associated with the clustered regularly interspaced short palindromic repeats. J Biol Chem. 2008;283(29):20361–20371.
Staals RJ, Agari Y, Maki-Yonekura S, et al. Structure and activity of the RNA-targeting type Ⅲ-B CRISPR-Cas complex of Thermus thermophilus. Mol Cell. 2013;52(1):135–145.
Makarova KS, Wolf YI, Alkhnbashi OS, et al. An updated evolutionary classification of CRISPReCas systems. Nat Rev Microbiol. 2015;13(11):722–736.
Jinek M, Jiang F, Taylor DW, et al. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science. 2014;343(6176):1247997.
Szczelkun MD, Tikhomirova MS, Sinkunas T, et al. Direct observation of R-loop formation by single RNA-guided Cas9 and Cascade effector complexes. Proc Natl Acad Sci U S A. 2014;111(27):9798–9803.
Gasiunas G, Barrangou R, Horvath P, et al. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A. 2012;109(39):E2579–E2586.
Jinek M, East A, Cheng A, et al. RNA-programmed genome editing in human cells. Elife. 2013;2:e00471.
Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823–826.
Sung P, Klein H. Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nat Rev Mol Cell Biol. 2006;7(10):739–750.
Chang HHY, Pannunzio NR, Adachi N, et al. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017;18(8):495–506.
Canver MC, Bauer DE, Dass A, et al. Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. J Biol Chem. 2014;289(31):21312–21324.
Liu Y, Zou RS, He S, et al. Very fast CRISPR on demand. Science. 2020;368(6496):1265–1269.
Wang AS, Chen LC, Wu RA, et al. The histone chaperone FACT induces Cas9 multi-turnover behavior and modifies genome manipulation in human cells. Mol Cell. 2020;79(2):221–233.e5.
Clarke R, Heler R, MacDougall MS, et al. Enhanced bacterial immunity and mammalian genome editing via RNA-polymerase-mediated dislodging of Cas9 from double-strand DNA breaks. Mol Cell. 2018;71(1):42–55.e8.
Ceccaldi R, Rondinelli B, D’Andrea AD. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol. 2016;26(1):52–64.
Scully R, Panday A, Elango R, et al. DNA double-strand break repair-pathway choice in somatic mammalian cells. Nat Rev Mol Cell Biol. 2019;20(11):698–714.
Yeh CD, Richardson CD, Corn JE. Advances in genome editing through control of DNA repair pathways. Nat Cell Biol. 2019;21(12):1468–1478.
Peterson SE, Li Y, Chait BT, et al. Cdk1 uncouples CtIP-dependent resection and Rad51 filament formation during M-phase double-strand break repair. J Cell Biol. 2011;194(5):705–720.
Song J, Yang D, Xu J, et al. RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency. Nat Commun. 2016;7:10548.
Maruyama T, Dougan SK, Truttmann MC, et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol. 2015;33(5):538–542.
Aylon Y, Liefshitz B, Kupiec M. The CDK regulates repair of double-strand breaks by homologous recombination during the cell cycle. EMBO J. 2004;23(24):4868–4875.
Ira G, Pellicioli A, Balijja A, et al. DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1. Nature. 2004;431(7011):1011–1017.
Müller M, Lee CM, Gasiunas G, et al. Streptococcus thermophilus CRISPR-Cas9 systems enable specific editing of the human genome. Mol Ther. 2016;24(3):636–644.
Qi L, Larson M, Gilbert L, et al. Repurposing CRISPR as an RNAguided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173–1183.
Chavez A, Scheiman J, Vora S, et al. Highly efficient Cas9-mediated transcriptional programming. Nat Methods. 2015;12(4):326–328.
Gilbert L, Larson M, Morsut L, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154(2):442–451.
Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods. 2013;10(10):957–963.
Alerasool N, Segal D, Lee H, et al. An efficient KRAB domain for CRISPRi applications in human cells. Nat Methods. 2020;17(11):1093–1096.
Saifaldeen M, Al-Ansari DE, Ramotar D, et al. CRISPR FokI dead Cas9 system: principles and applications in genome engineering. Cells. 2020;9(11):2518.
Komor AC, Badran AH, Liu DR. CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell. 2017;168(1–2):20–36.
Song F, Stieger K. Optimizing the DNA donor template for homology-directed repair of double-strand breaks. Mol Ther Nucleic Acids. 2017;7:53–60.
Bollen Y, Post J, Koo BK, et al. How to create state-of-the-art genetic model systems: strategies for optimal CRISPR-mediated genome editing. Nucleic Acids Res. 2018;46(13):6435–6454.
Nishida K, Arazoe T, Yachie N, et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science. 2016;353(6305):aaf8729.
Komor AC, Kim YB, Packer MS, et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420–424.
Gaudelli NM, Komor AC, Rees HA, et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464–471.
Li C, Zong Y, Wang Y, et al. Expanded base editing in rice and wheat using a Cas9-adenosine deaminase fusion. Genome Biol. 2018;19:59.
Nuñez JK, Chen J, Pommier GC, et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell. 2021;184(9):2503–2519.e17.
Liu X, Zhang Y, Chen Y, et al. In situ capture of chromatin interactions by biotinylated dCas9. Cell. 2017;170(5):1028–1043.e19.
Guiro J, Fagbemi M, Tellier M, et al. CAPTURE of the human U2 snRNA genes expands the repertoire of associated factors. Biomolecules. 2022;12(5):704.
Burramsetty AK, Nishimura K, Kishimoto T, et al. Locus-specific isolation of the Nanog chromatin identifies regulators relevant to pluripotency of mouse embryonic stem cells and reprogramming of somatic cells. Int J Mol Sci. 2022;23(23):15242.
Zetterberg H, Bendlin BB. Biomarkers for Alzheimer’s disease-preparing for a new era of disease-modifying therapies. Mol Psychiatr. 2021;26(1):296–308.
LaFerla FM, Oddo S. Alzheimer’s disease: abeta, tau and synaptic dysfunction. Trends Mol Med. 2005;11(4):170–176.
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–356.
Paquet D, Kwart D, Chen A, et al. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature. 2016;533(7601):125–129.
Sun L, Zhou R, Yang G, et al. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase. Proc Natl Acad Sci U S A. 2017;114(4):E476-E485.
Park H, Oh J, Shim G, et al. In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer’s disease. Nat Neurosci. 2019;22(4):524–528.
György B, Lööv C, Zaborowski MP, et al. CRISPR/Cas9 mediated disruption of the Swedish APP allele as a therapeutic approach for early-onset Alzheimer’s disease. Mol Ther Nucleic Acids. 2018;11:429–440.
Carr DB, Goate A, Phil D, et al. Current concepts in the pathogenesis of Alzheimer’s disease. Am J Med. 1997;103(3A):3S–10S.
Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74, 046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45(12):1452–1458.
Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–923.
Lin YT, Seo J, Gao F, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types. Neuron. 2018;98(6):1141–1154. e7.
Wadhwani AR, Affaneh A, van Gulden S, et al. Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in Alzheimer disease. Ann Neurol. 2019;85(5):726–739.
O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci. 2011;34:185–204.
Saito T, Matsuba Y, Mihira N, et al. Single App knock-in mouse models of Alzheimer’s disease. Nat Neurosci. 2014;17(5):661–663.
Viola KL, Klein WL. Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129(2):183–206.
Thal DR, Walter J, Saido TC, et al. Neuropathology and biochemistry of aβ and its aggregates in Alzheimer’s disease. Acta Neuropathol. 2015;129(2):167–182.
Wang M, Li A, Sekiya M, et al. Transformative network modeling of multi-omics data reveals detailed circuits, key regulators, and potential therapeutics for Alzheimer’s disease. Neuron. 2021;109(2):257–272. e14.
Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257–1272.
Hayes MT. Parkinson’s disease and Parkinsonism. Am J Med. 2019;132(7):802–807.
Taghavi S, Chaouni R, Tafakhori A, et al. A clinical and molecular genetic study of 50 families with autosomal recessive Parkinsonism revealed known and novel gene mutations. Mol Neurobiol. 2018;55(4):3477–3489.
Nuytemans K, Theuns J, Cruts M, et al. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat. 2010;31(7):763–780.
Scott L, Dawson VL, Dawson TM. Trumping neurodegeneration: targeting common pathways regulated by autosomal recessive Parkinson’s disease genes. Exp Neurol. 2017;298:191–201.
Nasrolahi A, Safari F, Farhoudi M, et al. Immune system and new avenues in Parkinson’s disease research and treatment. Rev Neurosci. 2019;30(7):709–727.
Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39(6):889–909.
Ishizu N, Yui D, Hebisawa A, et al. Impaired striatal dopamine release in homozygous Vps35 D620N knock-in mice. Hum Mol Genet. 2016;25(20):4507–4517.
Zhu XX, Zhong YZ, Ge YW, et al. CRISPR/Cas9-mediated generation of Guangxi Bama minipigs harboring three mutations in α-synuclein causing Parkinson’s disease. Sci Rep. 2018;8:12420.
Bonifati V, Breedveld GJ, Squitieri F, et al. Localization of autosomal recessive early-onset Parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Ann Neurol. 2002;51(2):253–256.
Chen ZZ, Wang JY, Kang Y, et al. PINK1 gene mutation by pair truncated sgRNA/Cas9-D10A in cynomolgus monkeys. Zool Res. 2021;42(4):469–477.
Wulansari N, Darsono WHW, Woo HJ, et al. Neurodevelopmental defects and neurodegenerative phenotypes in human brain organoids carrying Parkinson’s disease-linked DNAJC6 mutations. Sci Adv. 2021;7(8):eabb1540.
Oh CK, Dolatabadi N, Cieplak P, et al. S-nitrosylation of p62 inhibits autophagic flux to promote α-synuclein secretion and spread in Parkinson’s disease and Lewy body dementia. J Neurosci. 2022;42(14):3011–3024.
Jo J, Yang L, Tran HD, et al. Lewy body-like inclusions in human midbrain organoids carrying glucocerebrosidase and α-synuclein mutations. Ann Neurol. 2021;90(3):490–505.
Jowaed A, Schmitt I, Kaut O, et al. Methylation regulates alpha-synuclein expression and is decreased in Parkinson’s disease patients’ brains. J Neurosci. 2010;30(18):6355–6359.
Guhathakurta S, Kim J, Adams L, et al. Targeted attenuation of elevated histone marks at SNCA alleviates α-synuclein in Parkinson’s disease. EMBO Mol Med. 2021;13(2):e12188.
Yoon HH, Ye S, Lim S, et al. CRISPR-Cas9 gene editing protects from the A53T-SNCA overexpression-induced pathology of Parkinson’s disease in vivo. CRISPR J. 2022;5(1):95–108.
Ryan S, Dolatabadi N, Chan S, et al. Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription. Cell. 2013;155(6):1351–1364.
Delgado-Camprubi M, Esteras N, Soutar MP, et al. Deficiency of Parkinson’s disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation. Cell Death Differ. 2017;24(1):120–131.
Ma KY, Fokkens MR, Reggiori F, et al. Parkinson’s disease-associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy. Transl Neurodegener. 2021;10:19.
Basu S, Adams L, Guhathakurta S, et al. A novel tool for monitoring endogenous alpha-synuclein transcription by NanoLuciferase tag insertion at the 3’end using CRISPR-Cas9 genome editing technique. Sci Rep. 2017;8:45883.
Fields E, Vaughan E, Tripu D, et al. Gene targeting techniques for Huntington’s disease. Ageing Res Rev. 2021;70:101385.
Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin lowering strategies for disease modification in Huntington’s disease. Neuron. 2019;101(5):801–819.
Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83–98.
Crook ZR, Housman D, Huntington’s disease. Can mice lead the way to treatment? Neuron. 2011;69(3):423–435.
Farshim PP, Bates GP. Mouse models of Huntington’s disease. Methods Mol Biol. 2018;1780:97–120.
Levine MS, Cepeda C, Hickey MA, et al. Genetic mouse models of Huntington’s and Parkinson’s diseases: illuminating but imperfect. Trends Neurosci. 2004;27(11):691–697.
Yan S, Tu Z, Liu Z, et al. A huntingtin knockin pig model recapitulates features of selective neurodegeneration in Huntington’s disease. Cell. 2018;173(4):989–1002. e13.
Dabrowska M, Juzwa W, Krzyzosiak WJ, et al. Precise excision of the CAG tract from the huntingtin gene by Cas9 nickases. Front Neurosci. 2018;12:75.
Yang S, Chang R, Yang H, et al. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease. J Clin Invest. 2017;127(7):2719–2724.
Wang G, Liu X, Gaertig MA, et al. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc Natl Acad Sci U S A. 2016;113(12):3359–3364.
Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011;10(1):31–42.
Liu H, Zhang C, Xu J, et al. Huntingtin silencing delays onset and slows progression of Huntington’s disease: a biomarker study. Brain. 2021;144(10):3101–3113.
Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013;15(Suppl 2):ⅱ1–ⅱ56.
Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13(6):370–383.
June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73.
Wang D, Prager BC, Gimple RC, et al. CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies. Cancer Discov. 2021;11(5):1192–1211.
Larson RC, Kann MC, Bailey SR, et al. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature. 2022;604(7906):563–570.
Rosenblum D, Gutkin A, Kedmi R, et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv. 2020;6(47):eabc9450.
Tang F, Hartz AMS, Bauer B. Drug-resistant epilepsy: multiple hypotheses, few answers. Front Neurol. 2017;8:301.
Manford M. Recent advances in epilepsy. J Neurol. 2017;264(8):1811–1824.
Kefauver JM, Ward AB, Patapoutian A. Discoveries in structure and physiology of mechanically activated ion channels. Nature. 2020;587(7835):567–576.
Thijs RD, Surges R, O’Brien TJ, et al. Epilepsy in adults. Lancet. 2019;393(10172):689–701.
Wykes RC, Heeroma JH, Mantoan L, et al. Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Sci Transl Med. 2012;4(161):161ra152.
Colasante G, Qiu Y, Massimino L, et al. In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy. Brain. 2020;143(3):891–905.
Hansen KF, Sakamoto K, Pelz C, et al. Profiling status epilepticus-induced changes in hippocampal RNA expression using high-throughput RNA sequencing. Sci Rep. 2014;4:6930.
Hawkins NA, Calhoun JD, Huffman AM, et al. Gene expression profiling in a mouse model of Dravet syndrome. Exp Neurol. 2019;311:247–256.
Hawkins NA, Misra SN, Jurado M, et al. Epilepsy and neurobehavioral abnormalities in mice with a dominant-negative KCNB1 pathogenic variant. Neurobiol Dis. 2021;147:105141.
Lagae L. Dravet syndrome. Curr Opin Neurol. 2020;34(2):213–218.
Dravet C. Dravet syndrome history. Dev Med Child Neurol. 2011;53(Suppl 2):1–6.
Cetica V, Chiari S, Mei D, et al. Clinical and genetic factors predicting Dravet syndrome in infants with SCN1A mutations. Neurology. 2017;88(11):1037–1044.
Colasante G, Lignani G, Brusco S, et al. dCas9-based Scn1a gene activation restores inhibitory interneuron excitability and attenuates seizures in Dravet syndrome mice. Mol Ther. 2020;28(1):235–253.
Griffin A, Carpenter C, Liu J, et al. Phenotypic analysis of catastrophic childhood epilepsy genes. Commun Biol. 2021;4:680.
Leu C, Stevelink R, Smith AW, et al. Polygenic burden in focal and generalized epilepsies. Brain. 2019;142(11):3473–3481.
Zhang YH, Burgess R, Malone JP, et al. Genetic epilepsy with febrile seizures plus: refining the spectrum. Neurology. 2017;89(12):1210–1219.
Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Prim. 2017;3:17071.
Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;364(6435):362.
DeJesus-Hernandez M, MacKenzie I, Boeve B, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245–256.
Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668–1672.
Kwiatkowski Jr TJ, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205–1208.
Zhu Q, Jiang J, Gendron TF, et al. Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nat Neurosci. 2020;23(5):615–624.
Krishnan G, Zhang Y, Gu Y, et al. CRISPR deletion of the C9ORF72 promoter in ALS/FTD patient motor neurons abolishes production of dipeptide repeat proteins and rescues neurodegeneration. Acta Neuropathol. 2020;140(1):81–84.
Pinto BS, Saxena T, Oliveira R, et al. Impeding transcription of expanded microsatellite repeats by deactivated Cas9. Mol Cell. 2017;68(3):479–490. e5.
Perkins EM, Burr K, Banerjee P, et al. Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction. Mol Neurodegener. 2021;16:13.
Pickles S, Vande Velde C. Misfolded SOD1 and ALS: zeroing in on mitochondria. Amyotroph Lateral Scler. 2012;13(4):333–340.
Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162–172.
Kato S, Kato M, Abe Y, et al. Redox system expression in the motor neurons in amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS, superoxide dismutase 1 (SOD1)-mutated familial ALS, and SOD1-mutated ALS animal models. Acta Neuropathol. 2005;110(2):101–112.
Gaj T, Ojala DS, Ekman FK, et al. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci Adv. 2017;3(12):eaar3952.
Duan W, Guo M, Yi L, et al. The deletion of mutant SOD1 via CRISPR/Cas9/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model. Gene Ther. 2020;27(3–4):157–169.
Lim CKW, Gapinske M, Brooks AK, et al. Treatment of a mouse model of ALS by in vivo base editing. Mol Ther. 2020;28(4):1177–1189.
京公网安备11010802044758号